Skip to main content
. 2014 Dec 31;113(6):1697–1711. doi: 10.1152/jn.00752.2014

Fig. 10.

Fig. 10.

D1R agonist SKF81297 facilitates the middle striatum-evoked striatonigral IPSCs more strongly in Pitx3Null mice than in Pitx3WT mice. A and B: averaged traces of the middle striatum-evoked striatonigral IPSCs before, during and after bath application of 1 μM SKF81297 in Pitx3WT mice and Pitx3Null mice, respectively. C: pooled data showing 1 μM SKF81297 had a stronger facilitatory effect on the middle striatum-evoked striatonigral IPSCs in Pitx3Null mice (n = 9 cells) than in Pitx3WT mice (n = 7 cells). **P < 0.01, paired t-test. D: pooled data showing 1 μM SKF81297 decreased PPR in Pitx3WT and Pitx3Null mice. **P < 0.01, paired t-test. For the PPR during baseline and SKF81297 in Pitx3WT and Pitx3Null mice, P > 0.05, unpaired t-test.